Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Radiation Prior to Chimeric Antigen Receptor T-Cell Therapy Is an Optimizing Bridging Strategy in Relapse/Refractory Aggressive B-Cell Lymphoma

Qiuxia Yu, Xiaoying Zhang, Na Wang, Liang Huang, Chunrui Li, Yicheng Zhang, Jianfeng Zhou, Gaoxiang Wang, Yang Cao

Blood (2022) 140 (Supplement 1): 10311–10312.

DOI: https://doi.org/10.1182/blood-2022-165174

Published: 2022

Journal Articles

Be Cautious to Adopt a Second CAR T-Cell Infusion after Failure of CD19/CD22 Cocktail CAR T-Cell Therapy in Relapsed/Refractory B-NHL

Xin Yang, Gaoxiang Wang, Xiaoying Zhang, Qiuxia Yu, Yang Cao, Liang Huang

Blood (2022) 140 (Supplement 1): 4604–4605.

DOI: https://doi.org/10.1182/blood-2022-168419

Published: 2022

Journal Articles

Olverembatinib Based Therapy in Recurrent Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR/ABL Mutation

Qiuxia Lv, Qiuxia Yu, Yang Cao, Jue Wang, Yicheng Zhang, Gaoxiang Wang, Zhenya Hong, Li Meng

Blood (2022) 140 (Supplement 1): 11688–11689.

DOI: https://doi.org/10.1182/blood-2022-157416

Published: 2022

Journal Articles

Outcomes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) Patients with TP53 Gene Disruption Treated with CD19/22 Cocktail CAR T-Cell Therapy Alone or Incorporated with Autologous Stem Cell Transplantation (ASCT)

JIA Wei, Min Xiao, Zekai Mao, Yang Cao, Yi Xiao, Fankai Meng, Yicheng Zhang, Jianfeng Zhou, Liang Huang

Blood (2021) 138 (Supplement 1): 94.

DOI: https://doi.org/10.1182/blood-2021-147278

Published: 2021

Journal Articles

Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia

Blood (2021) 138 (17): 1535–1539.

DOI: https://doi.org/10.1182/blood.2021012953

Published: 2021

Includes: Supplemental data

Journal Articles

CD19/CD22 CAR-T Cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory B-Cell Lymphomas

Yang Cao, Yi Xiao, Na Wang, MD PhD, Gaoxiang Wang, MDPhD, Xiaoxi Zhou, MDPhD, Liang Huang, MD, Liting Chen, PhD, Min Xiao, MD PhD, Tongcun Zhang, PhD, Yicheng Zhang, Jianfeng Zhou, MD PhD

Blood (2020) 136 (Supplement 1): 11.

DOI: https://doi.org/10.1182/blood-2020-140308

Published: 2020

Journal Articles

Anti CD19/22 Cocktail CAR T-Cell Therapy Can Improve the Outcomes of Patients with TP53-Mutated Relapsed/Refractory B-Cell Lymphoma

JIA Wei, MDPhD, Min Xiao, Zekai Mao, Na Wang, MD PhD, Chunrui Li, MDPhD, Yang Cao, Weimin Sun, Yi Xiao, Chaojiang Gu, Shangkun Zhang, PhD, Yicheng Zhang, Tongcun Zhang, PhD, Jianfeng Zhou, MD PhD, Liang Huang, MD

Blood (2020) 136 (Supplement 1): 43.

DOI: https://doi.org/10.1182/blood-2020-138947

Published: 2020

Journal Articles

Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy

Wenyue Cao, Jia Wei, Na Wang, Hao Xu, Min Xiao, Lifang Huang, Yang Cao, Chunrui Li, Yi Xiao, Chaojiang Gu, Shangkun Zhang, Dengju Li, Yichen Zhang, Tongcun Zhang, Jianfeng Zhou, Liang Huang

Blood (2020) 136 (4): 516–519.

DOI: https://doi.org/10.1182/blood.2020004907

Published: 2020

Includes: Supplemental data

Journal Articles

Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies

Blood (2020) 135 (1): 17–27.

DOI: https://doi.org/10.1182/blood.2019000017

Published: 2020

Includes: Supplemental data

Journal Articles

Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells Following Autologous HSCT in Patients with B-NHL

Yang Cao, Na Wang, MD PhD, Gaoxiang Wang, MD PhD, Yi Xiao, MD PhD, Liang Huang, MD PhD, Chunrui Li, MD PhD, Min Xiao, MD PhD, Tongcun Zhang, PhD, Yicheng Zhang, MD PhD, Jianfeng Zhou, MD PhD

Blood (2018) 132 (Supplement 1): 2054.

DOI: https://doi.org/10.1182/blood-2018-99-113827

Published: 2018

Journal Articles

CAR22/19 Cocktail Therapy for Patients with Refractory/Relapsed B-Cell Malignancies

Liang Huang, MDPhD, Na Wang, MD PhD, Yang Cao, Chunrui Li, MDPhD, Yi Xiao, MD PhD, Min Xiao, MD PhD, Xiaoxi Zhou, MD, PhD, Gaoxiang Wang, MDPhD, Zhenya Hong, MD, PhD, Miao Zhen, MD, PhD, Weixu Meng, MD PhD, Bin Zhang, PhD, Yicheng Zhang, MDPhD, Guido Marcucci, Tongcun Zhang, PhD, Jianfeng Zhou, PhD

Blood (2018) 132 (Supplement 1): 1408.

DOI: https://doi.org/10.1182/blood-2018-99-113714

Published: 2018

Journal Articles

Myosin IIa is critical for cAMP-mediated endothelial secretion of von Willebrand factor

Pin Li, Guoqin Wei, Yang Cao, Qiuping Deng, Xiaofan Han, Xiaoshuai Huang, Yingqing Huo, Yulong He, Liangyi Chen, Jincai Luo

Blood (2018) 131 (6): 686–698.

DOI: https://doi.org/10.1182/blood-2017-08-802140

Published: 2018

Includes: Multimedia, Supplemental data

Journal Articles

Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for Adult Patients with Refractory/Relapsed B-Cell Acute Lymphoblastic Leukemia

Liang Huang, MD PhD, Na Wang, MD PhD, Chunrui Li, MD PhD, Yang Cao, MD PhD, Yi Xiao, MD PhD, Min Xiao, MD PhD, Yicheng Zhang, MD PhD, Tongcun Zhang, PhD, Jianfeng Zhou, MD PhD

Blood (2017) 130 (Suppl_1): 846.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.846.846

Published: 2017

Journal Articles

Whole Genome and Transcriptome Analysis of Waldenstrom's Cell Lines Show Preservation of Many Important Genomic Features of Primary Disease, and Identify a Non-L265P Mutation in MYD88

Zachary Hunter, PhD, Yang Cao, MD, Guang Yang, PhD, Xia Liu, MD, Jie Chen, PhD, Lian Xu, Nicholas Tsakmaklis, Jiaji Chen, Christopher J Patterson, MFA, Jorge J Castillo, MD, Steven P Treon, MD PhD

Blood (2015) 126 (23): 2665.

DOI: https://doi.org/10.1182/blood.V126.23.2665.2665

Published: 2015

Journal Articles

The Clonal Architecture of CXCR4mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability

Blood (2015) 126 (23): 1486.

DOI: https://doi.org/10.1182/blood.V126.23.1486.1486

Published: 2015

Journal Articles

Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia

Steven P. Treon, Christina K. Tripsas, Kirsten Meid, Sandra Kanan, Patricia Sheehy, Stacey Chuma, Lian Xu, Yang Cao, Guang Yang, Xia Liu, Christopher J. Patterson, Diane Warren, Zachary R. Hunter, Barry Turnbull, Irene M. Ghobrial, Jorge J. Castillo

Blood (2014) 124 (4): 503–510.

DOI: https://doi.org/10.1182/blood-2014-03-566273

Published: 2014

Journal Articles

Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia

Steven P. Treon, Yang Cao, Lian Xu, Guang Yang, Xia Liu, Zachary R. Hunter

Blood (2014) 123 (18): 2791–2796.

DOI: https://doi.org/10.1182/blood-2014-01-550905

Published: 2014

Journal Articles

The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis

Zachary R. Hunter, Lian Xu, Guang Yang, Yangsheng Zhou, Xia Liu, Yang Cao, Robert J. Manning, Christina Tripsas, Christopher J. Patterson, Patricia Sheehy, Steven P. Treon

Blood (2014) 123 (11): 1637–1646.

DOI: https://doi.org/10.1182/blood-2013-09-525808

Published: 2014

Includes: Supplemental data

Journal Articles

A Prospective Multicenter Study Of The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom’s Macroglobulinemia

Steven Peter Treon, MD, MA, PhD, Christina K Tripsas, MA, Guang Yang, PhD, Yang Cao, MD, Lian Xu, Zachary Hunter, Steven J Cropper, Patrick Mostyn, Kirsten Meid, MPH, Diane Warren, Christopher Patterson, Gaurav Varma, MSPH, Jacob P. Laubach, MD, Claudia E. Paba-Prada, MD, Janet Kunsman, NP, Irene M. Ghobrial, MD, Sandra Kanan, NP, Ranjana H. Advani, MD, Maria Lia Palomba, MD

Blood (2013) 122 (21): 251.

DOI: https://doi.org/10.1182/blood.V122.21.251.251

Published: 2013

Journal Articles

PI3K/AKT Pathway Is Activated By MYD88 L265P and Use Of PI3K-Delta Inhibitors Induces Robust Tumor Cell Killing In Waldenstrom’s Macroglobulinemia

Guang Yang, PhD, Xia Liu, MD, Yangsheng Zhou, MD, Lian Xu, Yang Cao, MD, Robert Manning, Christopher Patterson, Christina K Tripsas, MA, Zachary Hunter, Sara Buhrlage, Ph.D, Nathanael S Gray, PhD, Steven Peter Treon, MD, MA, PhD

Blood (2013) 122 (21): 4255.

DOI: https://doi.org/10.1182/blood.V122.21.4255.4255

Published: 2013

NARROW

Radiation Prior to Chimeric Antigen Receptor T-Cell Therapy Is an Optimizing Bridging Strategy in Relapse/Refractory Aggressive B-Cell Lymphoma

Be Cautious to Adopt a Second CAR T-Cell Infusion after Failure of CD19/CD22 Cocktail CAR T-Cell Therapy in Relapsed/Refractory B-NHL

Olverembatinib Based Therapy in Recurrent Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR/ABL Mutation

Outcomes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) Patients with TP53 Gene Disruption Treated with CD19/22 Cocktail CAR T-Cell Therapy Alone or Incorporated with Autologous Stem Cell Transplantation (ASCT)

Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia

CD19/CD22 CAR-T Cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory B-Cell Lymphomas

Anti CD19/22 Cocktail CAR T-Cell Therapy Can Improve the Outcomes of Patients with TP53-Mutated Relapsed/Refractory B-Cell Lymphoma

Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy

Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies

Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells Following Autologous HSCT in Patients with B-NHL

CAR22/19 Cocktail Therapy for Patients with Refractory/Relapsed B-Cell Malignancies

Myosin IIa is critical for cAMP-mediated endothelial secretion of von Willebrand factor

Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for Adult Patients with Refractory/Relapsed B-Cell Acute Lymphoblastic Leukemia

Whole Genome and Transcriptome Analysis of Waldenstrom's Cell Lines Show Preservation of Many Important Genomic Features of Primary Disease, and Identify a Non-L265P Mutation in MYD88

The Clonal Architecture of CXCR4mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability

Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia

Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia

The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis

A Prospective Multicenter Study Of The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom’s Macroglobulinemia

PI3K/AKT Pathway Is Activated By MYD88 L265P and Use Of PI3K-Delta Inhibitors Induces Robust Tumor Cell Killing In Waldenstrom’s Macroglobulinemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only